AbbVie Parkinson’s drug helps improve symptoms in late-stage study

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.

In the Phase 3 trial, early-stage Parkinson’s patients on the highest dose of the drug, called tavapadon, experienced a 10.2-point improvement on tests that measured motor symptoms and quality of life, also known as the MDS-UPDRS parts II and III. Meanwhile, those on placebo saw a 1.8-point worsening.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Teladoc Health & Microsoft Expands Generative AI Integration

What You Should Know: – Teladoc Health today announced an integration expansion with Microsoft, leveraging AI to help minimize administrative burden and identify potential hazards.

July 19, 2023

Mayo Clinic research shows health benefits of active workstations

A recent Mayo Clinic study suggests that active workstations incorporating a walking pad, bike, stepper and/or standing desk are successful strategies for reducing sedentary time

April 4, 2024

Life science VC Vertex Ventures HC raises $200M in new fund

Vertex Ventures HC is launching its largest fund yet, with $200 million and co-led by former pharma exec Christine Brennan. Vertex Ventures HC (VVHC) said

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.